From £500 to over £8,000 in 5 years! Should I invest in this precious metal for 2022?

This precious metal would have delivered outstanding returns over the last five years. Is there still an opportunity for investment now?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Rhodium is a very rare and precious metal that is predominately used to offset harmful nitrogen oxides in exhaust gases.

Over the last few years stricter emissions standards across the world, including in China and India, have led to a rise in demand. More stringent requirements mean that more rhodium is needed in catalytic converters to regulate greenhouse gas emissions.

The supply of the metal is also subject to constraints. First, the vast majority is produced in South Africa. Any commodity that is overly dependent on a single country for output is usually in short supply. Second, its processing is especially difficult due to its high melting point relative to other metals.

It’s no wonder that the price has skyrocketed over the last few years, when the demand has been strong against a backdrop of scarcity.

The ETC I’m looking at

I’m able to invest in rhodium through an ETC (exchange-traded commodity). This is a fund that tracks the price of a commodity but trades like a share that I can buy from most online brokers.

The ETC in question is db Physical Rhodium ETC (LSE: XRH0). It’s a small fund, being less than $100m in size. I also think it’s quite expensive, with a management charge of 0.95%.

However, the management charges pale into insignificance when looking at the past returns of this ETC.

A £500 investment in January 2016 would be worth around £8,000 today. By any measure, this is a phenomenal return. 

For 2022?

Supply is likely to increase as the strict Covid restrictions in South Africa subside. This is likely to be outstripped by an increase in demand.

Automakers are by far the biggest buyers of rhodium and over the last 12 months, car output has been restricted due to component shortages. Looking ahead, car output is likely to rise as the global semiconductor supply normalises, allowing car production to be ramped up.

This can be seen in the price action for 2022 already. At the time of writing, this ETC has increased by around 40% since the start of the new year.

However, further along the timeline, the picture is not so clear.

Over a longer time horizon, it’s clear that governments across the world will continue to pursue long-term carbon net-zero targets. This will probably lead to a decrease in the production of internal combustion engines requiring catalytic converters. Indeed over the last 12 months, the performance of this fund is broadly flat. 

It’s very likely that over the long term, the production and popularity of battery-electric and fuel-cell vehicles will probably grow. These don’t require catalytic converters.

I could be wrong, but for my own portfolio, I like to consider the long term. Since the demand for shares in this precious metal ETC seems uncertain, I will keep looking for alternative investments.

Niki Jerath does not own shares in db Physical Rhodium ETC. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle-aged white man pulling an aggrieved face while looking at a screen
Market Movers

Down 7%! Why on earth are Imperial Brands shares plummeting today?

Imperial Brands shares are in freefall after a negative reception to fresh trading news. Is the party finally over for…

Read more »

Rear View Of Woman Holding Man Hand during travel in cappadocia
Investing Articles

With a P/E under 7, this value stock looks far too cheap at 101p

This writer reckons value stock Hostelworld (LSE:HSW) looks dirt-cheap as it gets dividends flowing again and builds a social travel…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing For Beginners

Down 30% in 6 months, I think there’s a big catch to this insanely cheap stock

Jon Smith talks through why careful research is needed when trying to assess if a cheap stock is worth buying…

Read more »

Investing Articles

£5,000 invested in National Grid shares 5 years ago is now worth…

Andrew Mackie takes a closer look at National Grid shares and why short-term market weakness could be missing a powerful…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

How big does an ISA need to be to aim for a £1,500 monthly second income?

Harvey Jones shows how building a balanced portfolio of FTSE 100 dividend stocks can produce a high-and-rising second income in…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

£20,000 invested in BP shares 1 year ago is now worth…

BP shares have rocketed in the past 12 months, yet analysts think the real growth story is only just beginning,…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

A 6.8% forecast yield! 1 often-overlooked FTSE 100 income stock to buy today?

This income stock offers a high forecast yield and strengthening momentum, yet many investors overlook it — creating a rare…

Read more »

GSK scientist holding lab syringe
Investing Articles

GSK’s share price is under £22, but with a ‘fair value’ much higher, is it time for me to buy more right now? 

GSK’s share price rose over the last year, but a huge gap remains between its price and fair value —…

Read more »